What is the recommended treatment approach for psoriatic hand arthritis?

Treatment of Psoriatic Hand Arthritis

For psoriatic hand arthritis, initiate a TNF inhibitor biologic over conventional synthetic DMARDs (csDMARDs) as first-line therapy, particularly in patients with polyarticular involvement or poor prognostic factors such as erosive disease or elevated inflammatory markers. 1

Initial Treatment Algorithm

Treatment-Naive Patients with Active Hand Arthritis

Start with TNF inhibitor biologic monotherapy rather than methotrexate or other oral DMARDs, as TNF inhibitors demonstrate superior efficacy with larger effect sizes for peripheral joint disease 1. The 2018 ACR/NPF guidelines provide low-quality evidence supporting TNF inhibitors over oral synthetic DMARDs for treatment-naive active PsA 1.

Exception: If significant psoriatic skin involvement (body surface area ≥5% or involvement of critical areas like hands, face, nails) accompanies the hand arthritis, methotrexate may be preferred as the initial csDMARD due to its dual efficacy for skin and joints 1. However, TNF inhibitors remain more effective overall 1.

Adjunctive Symptomatic Therapy

• NSAIDs should be used for musculoskeletal symptom relief while initiating disease-modifying therapy 1
• Intra-articular glucocorticoid injections may be administered judiciously for persistently inflamed hand joints, avoiding injection through psoriatic plaques 1
• Systemic glucocorticoids should be used cautiously at the lowest effective dose due to risk of psoriasis flare upon discontinuation 1, 2

Poor Prognostic Factors Requiring Aggressive Treatment

Identify patients requiring immediate biologic therapy based on: 1

• Erosive disease on hand radiographs
• Elevated inflammatory markers (CRP or ESR) attributable to PsA
• Dactylitis (sausage digits) in the hands
• Nail involvement (pitting, onycholysis affecting 80-90% of PsA patients) 1
• Rapidly progressive disease with functional impairment
• Joint deformities causing functional limitation 1

Treatment Sequencing After TNF Inhibitor Failure

If Inadequate Response to First TNF Inhibitor

Switch to a different TNF inhibitor over switching to IL-17 inhibitor, IL-12/23 inhibitor, abatacept, or JAK inhibitor 1. This recommendation is based on low-quality evidence but represents the consensus approach 1.

Consider alternatives in specific scenarios: 1

• IL-17 inhibitor: If primary TNF inhibitor efficacy failure (no initial response), TNF-associated serious adverse event, or severe psoriasis
• IL-12/23 inhibitor: If primary TNF efficacy failure, serious adverse event, or patient prefers less frequent administration
• JAK inhibitor (tofacitinib): If patient prefers oral therapy, primary TNF failure, or serious adverse event
• Abatacept: If primary TNF failure or serious adverse event

If Inadequate Response to Second TNF Inhibitor

Switch to IL-17 inhibitor over IL-12/23 inhibitor for peripheral arthritis 1. IL-17 inhibitors demonstrate superior efficacy for both joint and skin manifestations compared to IL-12/23 inhibitors 1.

Exception: Consider IL-12/23 inhibitor if patient has inflammatory bowel disease (contraindication to IL-17 inhibitors) or prefers less frequent dosing 1.

After Biologic Failure

JAK inhibitors may be considered after inadequate response to at least one bDMARD, taking safety considerations into account, particularly cardiovascular risk, malignancy risk, and thromboembolic events in at-risk populations 1.

Role of Conventional Synthetic DMARDs

Methotrexate

• Conditional recommendation for use in polyarticular hand arthritis, particularly with clinically relevant skin involvement 1
• Evidence supporting methotrexate efficacy in PsA is limited to small, underpowered trials showing only moderate benefit 1
• May be added to TNF inhibitor monotherapy (especially monoclonal antibodies like infliximab or adalimumab) if partial response achieved 1

Other csDMARDs

• Sulfasalazine: Grade A evidence but limited efficacy; may be considered for mild peripheral arthritis 1
• Leflunomide: Grade A evidence with moderate efficacy 1
• Cyclosporine: Grade B evidence; limited to <12 consecutive months due to cumulative toxicity concerns 1

Hand-Specific Considerations

Distal Interphalangeal (DIP) Joint Involvement

Hand arthritis in PsA commonly affects DIP joints, which may be the only affected joints in some patients 1. DIP involvement often correlates with nail disease 1. TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors are strongly recommended for nail psoriasis, which frequently accompanies DIP arthritis 1.

Dactylitis Management

When hand dactylitis is present: 1

• Strong recommendation for TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors, JAK inhibitors, and PDE4 inhibitors
• Conditional recommendation for methotrexate, NSAIDs, and local glucocorticoid injections
• Head-to-head trials show no significant difference between TNF and IL-17 inhibitors for dactylitis resolution at 24 weeks 1

Arthritis Mutilans Risk

Some patients develop rapidly progressive destructive hand arthritis (arthritis mutilans) 1. Early aggressive treatment with biologics is critical to prevent irreversible joint destruction and functional disability 1, 3.

Monitoring and Treatment Targets

• Aim for remission or low disease activity through regular monitoring and treatment adjustment 1
• Assess response after 6 weeks of therapy initiation or modification 1, 4
• Evaluate for structural damage progression as greater disease activity correlates with progressive joint damage and higher mortality 1
• Early identification and treatment initiation are crucial for improving long-term outcomes 1

Common Pitfalls to Avoid

Do not delay biologic therapy in patients with polyarticular hand involvement, erosive disease, or poor prognostic factors while attempting sequential trials of oral DMARDs 1. The evidence supports earlier biologic use in these populations 1.

Do not use traditional oral DMARDs for axial disease if present alongside hand arthritis, as methotrexate, leflunomide, and sulfasalazine lack efficacy for axial manifestations 1, 4.

Avoid surgical intervention when possible, as hand surgery in PsA shows minimal improvement in motion and significantly increased infection rates compared to rheumatoid arthritis 3.

Do not substitute muscle relaxants or symptomatic therapy for inadequate disease control; reassess disease activity and escalate DMARD therapy per guidelines if musculoskeletal symptoms persist 5.

Multidisciplinary Collaboration

Rheumatologists should manage musculoskeletal manifestations, but collaboration with dermatologists is essential when clinically significant skin or nail involvement accompanies hand arthritis 1, 4. Treatment selection should account for efficacy across all affected domains (joints, skin, nails, entheses) 1.